Influence of Sacubitril/Valsartan on matrix metalloproteinase and left ventricular remodeling in heart failure with reduced ejection fraction patients
CHEN Shi-Yi
WANG Xiao-mei
LIU Yu
SUN Fei
Abstract：Objective To investigate the influence of Sacubitril/Valsartan on the level of matrix metalloproteinase(MMP)and left ventricular remodeling in heart failure with reduced ejection fraction(HFrEF)patients.Methods A total of 66 patients with HFrEF admitted from February 2020 to February 2021 were selected and randomly divided into Valsartan group(n=31)and Sacubitril/Val-sartan group(n=35).N-terminal pro-B-type natriuretic peptide(NT-proBNP),MMP-1,MMP-2 and MMP-9 were measured before the treatment and at 6-month follow-up.Left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),left ventricular end-diastolic volume(LVEDV)and left ventricular end-systolic volume(LVESV)were measured by echocardiogra-phy before the treatment and at 6-month follow-up.Results There was no significant difference in the dosage of Valsartan between the two groups at the initial follow-up and 6-month follow-up(P>0.05).At the 6-month follow-up,the level of MMP-9 in the Valsartan group was significantly lower than that before the treatment,and the difference was statistically significant(P<0.05).At the 6-month follow-up,the levels of NT-proBNP,MMP-1,MMP-2 and MMP-9 in the Sacubitril/Valsartan group were lower than those before the treatment,and lower than those in the Valsartan group,with statistical significance(P<0.05).At the 6-month follow-up,there were no significant differences in LVEF,LVEDD,LVEDV and LVESV in the Valsartan group compared with those before the treatment(P>0.05).At the 6-month follow-up,LVEF in the Sacubitril/Valsartan group was significantly higher than that before the treatment,and higher than that in the Valsartan group,while LVEDD,LVEDV and LVESV in the Sacubitril/Valsartan group were significantly lower than those before the treatment,and lower than those in the Valsartan group,and the differences were statistically significant(P<0.05).Conclusions Sacubitril/Valsartan can effectively improve left ventricular remodeling and left ventricular systolic function in HFrEF patients,and part of the mechanism is related to the inhibition of plasma MMP-1,MMP-2 and MMP-9 levels.
Keywords：Sacubitril/ValsartanHeart failure with reduced ejection fractionVentricular remodelingMatrix metalloproteinases
Publication Date：2023-10-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 328-331,335 )